Galectin 3: a potential biomarker for pulmonary arterial hypertension
TLDR
The hypothesis that Gal-3 predicts pulmonary artery pressure and right ventricular function in pulmonary arterial hypertension (PAH) is tested using a prospective study on 15 subjects with right heart failure.About:
This article is published in Journal of the American College of Cardiology.The article was published on 2014-04-01 and is currently open access. It has received 4 citations till now. The article focuses on the topics: Pulmonary artery.read more
Citations
More filters
Journal ArticleDOI
Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z.
Salvatore Sciacchitano,Salvatore Sciacchitano,Luca Lavra,Alessandra Morgante,Alessandra Ulivieri,Fiorenza Magi,Gian Paolo De Francesco,Carlo Bellotti,Leila B. Salehi,Leila B. Salehi,Alberto Ricci +10 more
TL;DR: The current review aims to extensively examine the studies published so far on the role of Gal-3 in all the clinical conditions and diseases, listed in alphabetical order, where it was analyzed.
Journal ArticleDOI
Galectin-3: A Link between Myocardial and Arterial Stiffening in Patients with Acute Decompensated Heart Failure?
TL;DR: Elevated galectin-3 levels correlate with severe systolic dysfunction and together with pulmonary hypertension are independent markers of outcome and may be predictive of raised pulmonary artery pressures.
Galectina-3: Ligação entre Rigidez Miocárdica e Arterial em Pacientes com Insuficiência Cardíaca Descompensada? Galectin-3: A Link between Myocardial and Arterial Stiffening in Patients with Acute Decompensated Heart Failure?
TL;DR: Elevated galectin-3 levels correlate with severe systolic dysfunction and together with pulmonary hypertension are independent markers of outcome and may be predictive of raised pulmonary artery pressures.
Journal ArticleDOI
Pulmonary hypertension in developing countries: Limiting factors in time to diagnosis, specialised medications and contextualised recommendations
TL;DR: Develop better screening tools, investigate novel therapeutics or novel drug targets, implement incentivised and accredited training for clinicians and implement awareness campaigns, which can help in developing countries where resources are limited and the healthcare burden is high.
Related Papers (5)
Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension.
Junichi Omura,Karima Habbout,Tsukasa Shimauchi,Wen-Hui Wu,Sandra Breuils-Bonnet,Eve Tremblay,Sandra Martineau,Valérie Nadeau,Kassandra Gagnon,Florence Mazoyer,Jean Perron,François Potus,Jianhui Lin,Hamza Zafar,Hamza Zafar,David G. Kiely,David G. Kiely,Allan Lawrie,Stephen L. Archer,Roxane Paulin,Steeve Provencher,Olivier Boucherat,Sébastien Bonnet +22 more